- Recruiting
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
Sponsor
ClinicalTrials.gov Identifier: NCT04973605
Official Title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
First Posted : July 22, 2021
Click here to see details on ClinicalTrials.gov
Bcl-2 Inhibitor BGB-11417 (Code C175489)
B-cell Lymphoma-2 Inhibitor BGB-11417
Bcl-2 Inhibitor BGB-11417
BGB 11417
BGB-11417
BGB11417
Drug: BGB-11417
Drug: Dexamethasone
Drug: Carfilzomib
Locations
United States, Alabama
United States, California
United States, Florida
United States, Georgia
United States, Illinois
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, New York
United States, Ohio
United States, Utah
United States, Washington
United States, Wisconsin
Australia, New South Wales
Australia, Victoria
Australia, Western Australia
AustraliaCanada, British Columbia
Canada, Ontario
Canada, Quebec
New Zealand